Intracranial Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Abstract

Selpercatinib has robust and durable intracranial efficacy in patients with <i>RET</i> fusion-positive NSCLC.